Please ensure Javascript is enabled for purposes of website accessibility
Home / Law / Pfizer rejected by Supreme Court on Neurontin marketing

Pfizer rejected by Supreme Court on Neurontin marketing

The U.S. Supreme Court left intact a $142 million award against Pfizer Inc. and let two similar suits go forward with claims that the drugmaker defrauded insurers by illegally marketing its Neurontin epilepsy drug.

Leave a Reply

Your email address will not be published. Required fields are marked *

*